Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program

BASEL, Switzerland, LONDON, and NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) -- Fast Company today announced its fifth annual Best Workplaces for Innovators list, honoring organizations and businesses that demonstrate an inspiring commitment to encourage and develop innovation at all levels. Roivant (Nasdaq: ROIV) came in at no. 25 on the list of 100 Best Workplaces for Innovators and is the winner on the Science and Technology list as a part of the Best Workplaces for Innovators program for its innovative business model and its unparalleled track record of 10 positive Phase 3 studies since 2019.

Developed in collaboration with Accenture, the 2023 Best Workplaces for Innovators ranks 100 winners from a variety of industries, including entertainment, biotech, consumer packaged goods, marketing, education, healthcare, and many more. Fast Company editors and Accenture researchers collaborated together to score nearly 1,000 submissions, and a panel of eight distinguished judges reviewed and endorsed the top 100 companies. The 2023 awards feature workplaces from around the world.

“We’re incredibly honored to receive this recognition. Roivant has always prided itself not only on our innovative business model but also on our commitment to fostering a culture that challenges convention and drives transformative change in the biopharma industry,” said Matt Gline, Roivant’s CEO.

Since Roivant’s founding in 2014, the company has achieved the following¹:

• The successful commercial launch of VTAMA®, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis
• 6 FDA approvals
• 10 positive Phase 3 trials (since 2019)
• An industry-leading inflammation and immunology pipeline with $15BN+ sales potential supported by VTAMA and multiple potential best- or first-in-class programs

"Innovation is a global priority, and this year's list has a decidedly international flavor,” says Brendan Vaughan, editor-in-chief of Fast Company. “Five of the top 10 ranked companies, including No. 1, Canva, are not headquartered in the U.S.”

To see the complete list, go to .

About Fast Company

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at .

About Accenture

Accenture is a global professional services company with leading capabilities in digital, cloud, and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Technology and Operations services, and Accenture Song—all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 710,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners, and communities. Visit us at .

About Roivant

Roivant is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Today, Roivant’s pipeline is concentrated in inflammation and immunology and includes VTAMA®, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (“FcRn”) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to several other therapies in various stages of clinical development. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit

Roivant Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our products and product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our products and product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Investors

Roivant Investor Relations

Media

Stephanie Lee

Roivant Sciences

¹ FDA approval and trial figures include Vants transferred to Sumitomo Pharma in December 2019.